To serve the growing global demand for pharmaceutical products and increased outsourcing of drug development and manufacturing, JLL pursued a vision to create a preeminent pharmaceutical contract development and manufacturing organization with global scale, end-to-end capabilities, and expertise to exceed even the most exacting customer and regulatory requirements.

Patheon’s transformational growth was enabled by both its enhanced leadership team and its merger with the pharmaceutical services division of Royal DSM, the Dutch nutrition and fine chemicals company, whose partnership unlocked significant new business opportunities.

With a relentless focus on flawless delivery, Patheon’s operational excellence program differentiated the business as the partner-of-choice for customers.

Through a series of nine transactions, Patheon not only dramatically increased its geographic footprint, but also elevated its positioning, servicing toward the highest growth parts of the market.